Zydus Therapeutics' Saroglitazar Receives FDA Priority Review
Decision brief
Answer first · skim in under a minute
Zydus Therapeutics' saroglitazar has received priority review from the US FDA, marking a significant regulatory milestone. This analysis explores the implications for investors and pharma teams.
Zydus Therapeutics’ saroglitazar has received U.S. FDA Priority Review—but for primary biliary cholangitis, not NASH. The May 28, 2026 announcement set a November 27, 2026 PDUFA date after EPICS-III showed a large biochemical-response gap versus placebo in UDCA inadequate responders.
Contents10 sections
Key Takeaways
- FDA Priority Review covers saroglitazar for PBC; PDUFA target action date is November 27, 2026.
- EPICS-III Phase 3 biochemical response: 56.7% on saroglitazar vs 9.8% on placebo (48% difference; p<0.001).
- Mean ALP fell 33.5% on drug versus a 6.5% rise on placebo (≈40.1% treatment difference).
- If approved, Zydus said it plans a U.S. launch by March 2027; the asset remains investigational until then.
What did the FDA actually accept for Priority Review?
According to Zydus’s May 28, 2026 PR Newswire release, the NDA seeks approval of saroglitazar for PBC in combination with ursodeoxycholic acid (UDCA) in adults with inadequate UDCA response, or as monotherapy in patients unable to tolerate UDCA.
Priority Review shortens FDA’s attention cycle for drugs that may meaningfully improve treatment of serious conditions. It is not an approval. Older summaries that framed this milestone as a June 2024 NASH Priority Review do not match the primary filing announcement and should be discarded.
What did EPICS-III show for saroglitazar in PBC?
EPICS-III (NCT05133336) is a multicenter, randomized, double-blind, placebo-controlled Phase 2b/3 study in adults with PBC who had inadequate response to or intolerance of UDCA. After dose selection, the Phase 3 analysis randomized patients 2:1 to saroglitazar magnesium 1 mg or placebo.
At Week 52, 56.7% of saroglitazar patients achieved the composite biochemical response versus 9.8% on placebo (treatment difference 48%; 95% CI 35.3–60.8; p<0.001). Composite response required ALP <1.67×ULN, at least a 15% ALP decrease from baseline, and bilirubin within ULN criteria. Among participants with baseline ALP ≤3×ULN, response rates were 83.1% versus 14.7%.
ALP change was also large: least-squares mean change favored saroglitazar by −124.1 U/L (−40.1%), reflecting a −33.5% reduction on drug versus a +6.5% increase on placebo. Week 24 pruritus improved on the 5-D Itch score (−5.9 vs −2.7; difference −3.2; p=0.009), though the Week 52 itch difference was not statistically significant.
How does safety look ahead of the PDUFA date?
Zydus said saroglitazar was generally well tolerated. Most treatment-emergent adverse events were mild to moderate. Serious adverse events occurred in 6.3% of saroglitazar patients versus 11.1% on placebo; investigators considered none treatment-related, and no treatment-related deaths were reported.
TEAEs occurring in more than 5% of patients and at least 2% more often on drug included headache, hypertension, upper respiratory tract infection, abdominal pain, COVID-19, diarrhea, and vitamin D deficiency. Label negotiations will focus on monitoring guidance for a PPAR α/γ agonist in a rare cholestatic population already exposed to UDCA and, increasingly, second-line agents.
Why the NASH mix-up matters for investors
Saroglitazar has a longer history in metabolic liver disease, including Indian NASH approval narratives and U.S. NAFLD/NASH exploratory work. That background likely seeded earlier incorrect framing that Priority Review applied to NASH. The May 2026 Priority Review package, however, is a PBC NDA supported by EPICS-III late-breaking presentation plans at EASL 2026.
Commercial models should therefore size the U.S. opportunity against second-line PBC competitors and ALP-response benchmarks, not against the much larger MASH population. Zydus still lists MASH among longer-term interests, but that is not the current FDA clock.
What remains unproven?
Priority Review does not guarantee approval. Long-term hard outcomes such as transplant-free survival were not the primary endpoint of the Week 52 biochemical package summarized here. Comparative effectiveness versus other second-line PBC therapies cannot be inferred from placebo-controlled data alone.
FDA’s own Priority Review policy page explains the process but does not replace product-specific review documents that will appear after action: see FDA Priority Review overview. Until November 27, 2026, treat launch-by-March-2027 statements as company planning, not regulatory fact.
Implications for pharma teams
- PDUFA date: November 27, 2026; planned U.S. launch target: March 2027 (company statement).
- Primary endpoint win: 56.7% vs 9.8% biochemical response (N=148 Phase 3 analysis).
- Mechanism: oral PPAR α/γ agonist with Orphan, Fast Track, and Priority Review designations for PBC.
- Registry: NCT05133336 (EPICS-III).
Medical affairs should scrub prior NASH-priority messaging. Competitive intelligence should map ALP response and itch endpoints against existing second-line PBC options before modeling share.
Related NovaPharma coverage
- Zydus Lifesciences Secures FDA Priority Review for Liver Disease Drug
- Can a Chaotic FDA Still Deliver on Faster Drug Development?
- ARCHIMED Acquires Esperion in Cardiometabolic Deal
Frequently Asked Questions
What indication did FDA grant Priority Review for saroglitazar?
On May 28, 2026, Zydus Therapeutics said the FDA granted Priority Review to an NDA for saroglitazar to treat primary biliary cholangitis (PBC) with UDCA in inadequate responders, or as monotherapy in UDCA-intolerant adults. The PDUFA target action date is November 27, 2026.
What did EPICS-III show for saroglitazar in PBC?
In the Phase 3 portion (N=148), 56.7% of saroglitazar-treated patients achieved biochemical response versus 9.8% on placebo, a 48% treatment difference (95% CI 35.3–60.8; p<0.001) at Week 52.
Is this Priority Review for NASH?
No. The May 2026 Priority Review and PDUFA date apply to the PBC NDA supported by EPICS-III (NCT05133336). Saroglitazar’s U.S. NASH/MASH program is separate and should not be conflated with this filing.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for saroglitazar.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
